All In Biotech

Drug Trial Radar · NCT04010539

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae

Last checked: Nov 20, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 628 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

628

Actual

Start

Oct 21, 2019

Primary completion

Oct 10, 2023

Study completion Oct 10, 2023

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, randomized, multicenter, open-label study which will be performed to evaluate efficacy and safety of oral Gepotidacin compared to intramuscular (IM) ceftriaxone plus oral azithromycin for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae (N. gonorrhoeae) in adolescent and adult participants. In this study, participants will be randomly assigned to receive either oral gepotidacin or IM ceftriaxone plus oral azithromycin.

Conditions

  • Gonorrhea

Interventions

  • GepotidacinDrug

    Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.

  • CeftriaxoneDrug

    Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.

  • AzithromycinDrug

    Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Culture-Confirmed Bacterial Eradication of Neisseria Gonorrhoeae (NG) From the Urogenital Site at the Test-Of-Cure (TOC) Visit (Day 4 to 8)Time frame: Baseline (Day 1) and TOC visit (Day 4 to 8)

Locations

51 sites in 6 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    DeLand, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Decatur, Georgia

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Springfield, Massachusetts

  • GSK Investigational Site

    Fayetteville, North Carolina

  • GSK Investigational Site

    Greensboro, North Carolina

  • GSK Investigational Site

    Cleveland, Ohio

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Longview, Texas

  • GSK Investigational Site

    Darlinghurst, New South Wales, Australia

  • GSK Investigational Site

    Darlinghurst, Sydney, New South Wales, Australia

  • GSK Investigational Site

    Southport, Queensland, Australia

  • GSK Investigational Site

    Carlton, Victoria, Australia

  • GSK Investigational Site

    Prahran, Victoria, Australia

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    München, Germany

  • GSK Investigational Site

    Munich, Bavaria, Germany

  • GSK Investigational Site

    Frankfurt am Main, Hesse, Germany

  • GSK Investigational Site

    Frankfurt am Main, Hesse, Germany

  • GSK Investigational Site

    Cologne, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Monterrey, Mexico

  • GSK Investigational Site

    Guadalajara, Jalisco, Mexico

  • GSK Investigational Site

    Guadalajara, Jalisco, Mexico

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Bilbao, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Madrid, Spain

  • GSK Investigational Site

    Seville, Spain

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.